Press Releases April 15, 2026 08:00 PM

The York Water Company Announces Pricing of 2026 Public Offering of Common Stock

York Water Prices 2026 Public Offering to Raise Approximately $43 Million

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
YORW

The York Water Company announced the pricing of its underwritten public offering of 1.52 million shares of common stock at $28.50 per share, expected to raise gross proceeds of approximately $43 million. The company has granted underwriters a 30-day option to purchase additional shares. Proceeds will be used for general corporate purposes including capital investments, debt repayment, and potential acquisitions.

The York Water Company Announces Pricing of 2026 Public Offering of Common Stock
YORW
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Offering totals 1,521,739 shares at $28.50 per share, raising around $43 million before costs.
  • Underwriters have a 30-day option to buy an additional 228,261 shares.
  • Proceeds will support capital investments, debt repayment, and potential acquisitions, enhancing company growth and financial flexibility.

YORK, Pa., April 16, 2026 (GLOBE NEWSWIRE) -- The York Water Company (“York Water” or the “Company”) (NASDAQ: YORW), a provider of water and wastewater utility services, announced today the pricing of its previously announced underwritten public offering of common stock. York Water priced an offering of 1,521,739 shares of its common stock at a price to the public of $28.50 per share. The aggregate gross proceeds from the offering are expected to be approximately $43 million, before deducting underwriting discounts and commissions payable by York Water. York Water has granted the underwriters a 30-day option to purchase up to 228,261 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.

York Water intends to use the net proceeds from the offering for general corporate purposes, including our capital investment program, repayment of outstanding indebtedness, and potential acquisitions.

Huntington Capital Markets is acting as sole book-running manager and Seaport Global Securities is acting as co-manager for the offering.

The offering is being made pursuant to an effective shelf registration statement filed with the Securities and Exchange Commission (the “SEC”) on Form S-3 (Registration No. 333-283488).

The offering may be made only by means of a prospectus supplement and an accompanying prospectus. A preliminary prospectus supplement relating to the offering has been filed with the SEC. Copies of the preliminary prospectus supplement and the accompanying prospectus may be obtained by visiting EDGAR on the SEC’s website at www.sec.gov or from: Huntington Securities, Inc., 41 South High Street, Columbus, OH 43215, or by email at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

This news release may contain forward-looking statements. The Company undertakes no duty to update any forward-looking statement. More information concerning forward-looking statements can be found in the Company’s filings with the SEC at sec.gov.


Risks

  • Market conditions may affect the success and pricing of the offering, which could impact the capital raised.
  • Use of proceeds for acquisitions carries integration and execution risks that might affect future performance.
  • Forward-looking statements contain uncertainties that may cause actual outcomes to differ from expectations.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026